Alpha-Asaronol Ester Synthesis for Neurological Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for senile dementia, convulsions, epilepsy, and depression lack effective chemical drugs that provide comprehensive brain protection and calming effects while resisting these conditions.
Innovation Solution
The development of α-Asaronol esters, specifically 3,4,5-trimethoxycinnamate α-Asaronol ester, through structural and pharmacophore combination, utilizing specific reaction conditions and catalysts to synthesize compounds for enhanced pharmacological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for senile dementia, convulsions, epilepsy, and depression are used, then some symptomatic relief may be achieved, but they lack comprehensive brain protection and calming effects
Solution Approach 1:
The patent combines the pharmacophore structures of TMCA (from Polygala tenuifolia) and α-asarone (from Acorus gramineus soland) into a single ester compound. This merging of two active moieties into one molecule allows the compound to simultaneously exhibit brain protection, calming, anticonvulsant, and anti-dementia effects, thereby achieving comprehensive treatment across multiple conditions with a single agent
Solution Approach 2:
The invention creates a composite molecular structure by esterifying the hydroxyl group of α-asarone with the carboxyl group of TMCA. This composite compound integrates the pharmacological properties of both parent compounds, producing synergistic effects that provide reliable brain protection and calming actions while resisting multiple neurological conditions
2Reliability
If structural combination of TMCA and α-asarone is performed to create ester derivatives, then pharmacological activity is enhanced, but the synthesis process becomes more complex
Solution Approach 1:
The synthesis is divided into clear sequential steps: first preparing the ester bond formation between TMCA and α-asarone, then isolating and purifying the product. This segmentation of the synthesis process into manageable stages simplifies the overall procedure while maintaining high pharmacological activity in the final product
Solution Approach 2:
The ester bond acts as an intermediary linkage connecting the TMCA pharmacophore with the α-asarone pharmacophore. This intermediary structure allows both active moieties to retain their pharmacological properties while enabling synergistic interactions, thus enhancing overall activity without requiring complex multi-component assemblies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The α-Asaronol esters demonstrate significant anticonvulsant activity, brain protection, and calming effects, offering improved treatment options for senile dementia, convulsions, epilepsy, and depression with a favorable safety profile.
Implementation Method 1
sequentially adding the compound of formula II, the compound of formula III and the catalyst in a molar ratio of 1.0 to 2.0 : 1.0 to 2.0 : 0.1 to 1.0 into a reaction vessel
Implementation Method 2
adding a dehydrating agent, wherein the molar ratio of the dehydrating agent to the compound of formula II is 1 to 2 : 1
Implementation Method 3
after completion of the reaction, extracting the reaction mixture with ethyl acetate/water to separate the organic phase
Implementation Method 4
which is then dried over anhydrous sodium sulfate
Data Source
AI summary
The present invention relates to α-asary-laldehyde ester, a preparation method therefor, and an application thereof. The chemical structure of the related α-asary-laldehyde ester is represented by formula I. A related application is an application of the compound in preparation of drugs for calming, mind tranquillizing, senile dementia resisting, convulsion resisting, epilepsy resisting and depression resisting.